Daily doses of finasteride—a drug known for its ability to regrow
hair—reduced the incidence of prostate cancer by 25% in men aged 55
years or older, according to data from a large trial sponsored by the National
Cancer Institute, Bethesda, Md.
The study appeared June 24 in the New England Journal
of Medicine's online edition (http://content.nejm.org/).
Originally scheduled to last through May 2004, the Prostate Cancer Prevention
Trial stopped in March after the data monitoring committee recommended an
early halt based on the good results. Some 19 000 men participated; half
received 5 mg of finasteride daily, half received placebo. After 7 years of
monitoring, pathologists (who were blinded to the intervention) analyzed biopsied
prostate tissue from the volunteers.
Vastag B. Finasteride Can Reduce Prostate Cancer Risk. JAMA. 2003;290(3):324. doi:10.1001/jama.290.3.324-a